MML Investors Services
GPCR icon

MML Investors Services’s Structure Therapeutics GPCR Stock Holding History

MML Investors Services’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$669K Buy
13,887
+6,062
+77% +$415K ﹤0.01% 2032
2025
Q4 		$544K Buy
+7,825
New +$319K ﹤0.01% 2207

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

MML Investors Services's GPCR Position: Q1 2026 in Review

MML Investors Services increased its Structure Therapeutics (GPCR) stake by 77% in Q1 2026, buying an estimated $415K and bringing the position to 13,887 shares worth $669K. The position accounts for ﹤0.01% of the portfolio, ranked #2032.

MML Investors Services first reported a position in GPCR in Q4 2025 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • MML Investors Services held 13,887 shares of Structure Therapeutics worth $669K as of Q1 2026.
  • MML Investors Services bought 6,062 Structure Therapeutics shares in Q1 2026, an estimated $415K.
  • Structure Therapeutics made up ﹤0.01% of MML Investors Services's portfolio in Q1 2026, its #2032 holding.
  • MML Investors Services first reported a position in Structure Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on MML Investors Services's 13F filing for Q1 2026, filed 4 May 2026.